TherapeuticsMD v. Teva: Imvexxy Patent Case Consolidated After 10 Days
TherapeuticsMD and Mayne Pharma filed suit against Teva in the District of New Jersey on December 13, 2024, asserting 9 patents covering Imvexxy estradiol vaginal inserts (4 mcg and 10 mcg). The case was closed within 10 days — not on the merits, but because all parties jointly requested consolidation into the long-running ANDA litigation docket originating in 2020.
A 10-Day Docket: New Imvexxy Patents Folded Into Teva ANDA Battle
On December 13, 2024, TherapeuticsMD, Inc. and Mayne Pharma LLC filed Civil Action No. 2:24-cv-11161 in the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc., asserting nine U.S. patents covering Imvexxy estradiol vaginal inserts at the 4 mcg and 10 mcg dosage strengths. This filing is the latest chapter in a multi-year ANDA patent dispute that began in April 2020.
The case terminated on December 23, 2024 — just ten days after filing — not through dismissal on the merits but via a joint consolidation order. Teva Ltd. was promptly dismissed by stipulation on December 18, 2024. Teva USA accepted service, and all three parties jointly requested that Civil Action Nos. 20-3485, 21-12794, and 24-11161 be consolidated, meaning the substantive patent dispute will proceed under the pre-existing dockets.
The speed of consolidation suggests the parties had coordinated procedurally before filing — a pattern consistent with ANDA litigation practice where new patent listings trigger new civil actions that are then folded into existing litigation. The public record does not reveal the current trial schedule or claim construction status in the consolidated actions, nor whether any licensing discussions are underway.
Filing to Case Consolidated in 10 days
10 days — closed by consolidation order, no merits adjudication at this docket number
Case consolidated: what the order means for both parties
Consolidation is procedural — the fight continues elsewhere
A consolidation order under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single proceeding. Here, Civil Action No. 24-11161 was folded into the existing Teva ANDA dockets (20-3485 and 21-12794). No merits ruling was made — the nine asserted patents remain actively in dispute before the same court under the consolidated docket.
No merits ruling issuedTherapeuticsMD and Mayne preserve all nine patent claims
Consolidation is typically a plaintiff-neutral procedural step. TherapeuticsMD and Mayne Pharma retain all infringement claims across the nine newly asserted patents. By joining the existing docket, plaintiffs avoid duplicative discovery and inconsistent rulings — a strategic advantage in a portfolio-heavy ANDA dispute spanning multiple patent families.
Claims intact, litigation continuesTeva faces expanded patent exposure in consolidated proceeding
For Teva USA, consolidation means the nine new patents from Civil Action No. 24-11161 are now litigated alongside the earlier asserted patents in the 2020 dockets. Teva Ltd. was dismissed by stipulation on December 18, 2024, narrowing the defendant parties. Teva USA must now contend with a broader patent portfolio in a single, potentially more complex consolidated proceeding.
Teva Ltd. dismissed; Teva USA remainsImvexxy patent fortress grows — generic entry timeline uncertain
With nine additional patents now consolidated into the ANDA litigation, the earliest potential generic entry date for estradiol vaginal inserts is likely extended pending resolution. The breadth of the asserted portfolio — covering formulation, dosage, and method claims across nine patents — suggests TherapeuticsMD and Mayne are pursuing a layered exclusivity strategy that raises the litigation cost and complexity for any generic challenger.
Generic entry timeline under pressureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Therapeuticsmd, Inc. | Company | Women’s health pharmaceutical company — holder of US11351182B2 and 8 further Imvexxy patentsSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer challenging Imvexxy estradiol vaginal insert patents via ANDASearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Therapeuticsmd, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Therapeuticsmd, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Therapeuticsmd, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a purely procedural disposition — no patent claims were adjudicated, no validity findings were made, and no infringement was admitted or denied. The joint request by all parties signals coordinated case management rather than adversarial resolution. The operative litigation will proceed under Civil Action Nos. 20-3485 and 21-12794, where the substantive merits of the Imvexxy patent portfolio will ultimately be tested.
US11351182B2 and 8 further patents — Imvexxy estradiol vaginal insert formulations
The nine asserted patents — including US11351182B2, US11497709B2, US11266661B2, US11065197B2, US11304959B2, US11241445B2, US11123283B2, US11116717B2, and US11246875B2 — cover the Imvexxy product line of low-dose estradiol vaginal inserts at 4 mcg and 10 mcg dosage strengths. The underlying applications were filed across 2018–2020, and the patents issued through 2022, suggesting a deliberate continuation strategy to build layered protection around the same commercial product.
Imvexxy is the first FDA-approved estradiol vaginal insert indicated for moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy. The nine-patent portfolio covering this product represents a significant exclusivity barrier for generic challengers. With Mayne Pharma now holding co-plaintiff status, the commercial rights landscape adds further complexity for any competitor seeking to design around or invalidate these patents in IPR or district court proceedings.
Should you run an FTO against the Imvexxy patent portfolio?
Any pharmaceutical company developing or commercialising a generic estradiol vaginal insert — particularly at 4 mcg or 10 mcg dosages — should treat this nine-patent portfolio as a high-priority FTO target. The breadth of the portfolio, spanning multiple application families filed between 2018 and 2020, means that design-around strategies must be evaluated across all nine patents, not in isolation. ANDA filers in particular face 30-month stay exposure on each newly issued patent.
PatSnap Eureka’s FTO Search Agent can map the full claim scope across all nine Imvexxy patents, identify prosecution history disclaimers, flag related continuation applications that may not yet have issued, and surface prior art relevant to validity challenges. For R&D teams working on vaginal drug delivery or hormone replacement formulations, proactive FTO analysis against this portfolio is commercially essential before filing any ANDA or initiating product development.
Run a freedom-to-operate analysis on US11351182B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: estradiol and women’s health pharma litigation
Related ANDA infringement actions involving estradiol formulations and women’s health pharmaceutical patents filed in the District of New Jersey.
What this case signals for the women’s health pharmaceutical IP landscape
The rapid consolidation of new ANDA suits into long-running dockets is a defining feature of pharmaceutical patent enforcement strategy.
Serial ANDA filings + consolidation is a deliberate portfolio enforcement tactic
TherapeuticsMD’s pattern of filing successive civil actions as new patents issue — and then consolidating them — is consistent with a rolling enforcement strategy. Each new patent filing resets the 30-month stay clock under Hatch-Waxman and expands the claims Teva must design around or invalidate. IP teams monitoring ANDA disputes should track not just the lead docket but all related filings.
Nine-patent portfolios in ANDA disputes signal strong FTO risk for generics
A nine-patent assertion over a single product (Imvexxy) indicates deep patent protection at the formulation, dosage, and method levels. Generic manufacturers considering an ANDA for estradiol vaginal inserts face a complex clearance landscape. FTO analysis must account for all nine patents and their claim scope, not just the lead patent, to accurately assess infringement risk.
Therapeuticsmd v Teva — key questions answered
Case 2:24-cv-11161 was filed on December 13, 2024 and closed on December 23, 2024 via a consolidation order. TherapeuticsMD and Mayne Pharma asserted nine patents covering Imvexxy estradiol vaginal inserts against Teva. No merits ruling was issued — the case was merged into the existing ANDA litigation dockets 20-3485 and 21-12794 pending in the District of New Jersey.
TherapeuticsMD and Mayne Pharma asserted nine patents in Civil Action No. 24-11161: US11351182B2, US11497709B2, US11266661B2, US11065197B2, US11304959B2, US11241445B2, US11123283B2, US11116717B2, and US11246875B2, all covering estradiol vaginal insert formulations at 4 mcg and 10 mcg dosage strengths sold under the Imvexxy brand.
Teva Ltd. was dismissed by stipulation on December 18, 2024, just five days after the complaint was filed. This follows a consistent pattern across all five related TherapeuticsMD v. Teva civil actions, in which Teva Ltd. (the Israeli parent entity) was dismissed early, leaving Teva Pharmaceuticals USA, Inc. as the sole remaining defendant. The public record does not specify the precise legal basis, but the pattern suggests a personal jurisdiction or service-related defence.
Consolidation under Fed. R. Civ. P. 42(a) means that Civil Action No. 24-11161 and its nine asserted patents are now litigated together with the earlier actions (20-3485 and 21-12794) in a single proceeding. No claims were dismissed — the infringement dispute continues before the same court. Consolidation typically streamlines discovery and reduces the risk of inconsistent rulings across related dockets.
Mayne Pharma LLC was added as a co-plaintiff in the existing Teva ANDA actions on July 13, 2023, and joined TherapeuticsMD as a co-plaintiff in the new Civil Action No. 24-11161 filed in December 2024. This suggests Mayne Pharma acquired rights to the Imvexxy patent portfolio or obtained an exclusive licence at some point before July 2023. The precise nature of Mayne’s interest is not detailed in the public docket.
PatSnap Eureka searches patents and litigation data to answer instantly.